Exhibit 10.17(a)
Dated 27th November 2000
-----------------------------------------------------------
CEPHALON (UK) LIMITED
- AND -
NOVARTIS PHARMACEUTICALS UK LIMITED
----------------------------------------
MANAGED SERVICES AGREEMENT
----------------------------------------
CMS Xxxxxxx XxXxxxx
Xxxxx Xxxxx
000 Xxxxxxxxxx Xxxxxx
Xxxxxx XX0X 0XX
T x00(0)00 0000 0000
F x00(0)00 0000 0000
Table of Contents
1. Definitions and Interpretation..................................1
2. Cephalon's Responsibilities and Obligations.....................7
3. Novartis' Responsibilities And Obligations......................8
4. Audit...........................................................9
5. Payment........................................................10
6. Data Protection................................................12
7. Rights.........................................................12
8. Duration and Termination.......................................13
9. Termination....................................................13
10. Consequences of Termination....................................14
11. Exclusion Of Implied Warranties................................14
12. Indemnity......................................................14
13. Force Majeure..................................................15
14. Sub-contracting................................................17
15. Notices........................................................17
16. Relationship of Parties........................................18
17. Waiver.........................................................19
18. Severability...................................................20
19. Third Party Rights.............................................20
20. Governing Law..................................................20
21. Transmission of Rights.........................................20
22. Variations.....................................................20
23. Counterparts...................................................21
Schedule 1 Services................................................23
Schedule 2 Charges.................................................25
Schedule 3 The Products............................................26
THIS AGREEMENT is made the 27th day of November 2000
BETWEEN:
(1) CEPHALON (UK) LIMITED (Registered no 3207745) a company incorporated in
England and Wales whose registered office is at 11/13 Xxxxxxxxx Xxxxxxx
Road, Surrey Xxxxxxxx Xxxx, Xxxxxxxxx, Xxxxxx XX0 0XX ("Cephalon"); and
(2) NOVARTIS PHARMACEUTICALS UK LIMITED ( Registered No 119006), a company
incorporated in England and Wales whose registered office is at Xxxxxxx
Xxxxxxxx Xxxx, Xxxxxxx, Xxxxxxxxx, Xxxxxx XX00 0XX ("Novartis").
WHEREAS:
Novartis has requested that Cephalon provide to Novartis certain marketing
and administrative services (as hereinafter defined more fully) to
Novartis and Cephalon has agreed to do so on the terms and conditions set
out below.
IT IS AGREED as follows:
1. Definitions and Interpretation
In this Agreement:
"Adverse Reaction" means a response to a substance that is noxious and
unintended and which occurs at doses normally used in man for prophylaxis,
diagnosis and therapy;
-1-
"Affiliate" means any company, partnership or other entity which directly
or indirectly Controls, is Controlled by or is under common Control with,
the party in question including as a Subsidiary or Holding Company.
"Agreement" means this agreement and any and all schedules, appendices and
other addenda to it as may be varied from time to time in accordance with
the provisions of this agreement.
"Charges" means the charges which are payable by Novartis for the Services
in accordance with the guidelines set out in Schedule 2 and as may be
amended by agreement between the Parties from time to time.
"Cephalon Product" means the pharmaceutical product shown in Part I of
Schedule 3.
"Commencement Date" means 1 January 2001.
"Control" means the ownership (direct or indirect) of more than 50% of the
issued share capital or the legal power to direct or cause the direction
of the general management and policies of the party in question and
"Controlled" and "Controller" shall be construed accordingly.
"Force Majeure" means in relation to any Party any event or circumstance
which is beyond the reasonable control of that Party which event the Party
could not reasonably be expected to have taken into account at the date of
this Agreement including acts of God, war, riot, civil commotion, any
overriding emergency, fire, flood, storm and industrial dispute (other
than industrial dispute affecting only the
-2-
employees of the Party suffering the event of force majeure or any of its
agents or subcontractors).
"Insolvency Event" in relation to any Party, means any one of the
following:
(a) a notice shall have been issued to convene a meeting for the purpose of
passing a resolution to wind up that Party or such a resolution shall have
been passed other than a resolution for the solvent reconstruction or
reorganisation of that Party; or
(b) a resolution (other than a resolution for the solvent reconstruction or
reorganisation of a Party) shall have been passed by that Party's
directors to seek a winding up or administration order or a petition for a
winding up or administration order shall have been presented against that
Party or such an order shall have been made; or
(c) a receiver, administrative receiver, receiver and manager, interim
receiver, custodian, sequestrator or similar officer is appointed in
respect of that Party or over a substantial part of its assets or any
third party takes steps to appoint such an officer in respect of that
Party or an encumbrancer takes steps to enforce or enforces its security;
or
(d) a proposal for a voluntary arrangement shall have been made in relation to
that Party under Part I Insolvency Xxx 0000; or
-3-
(e) a step or event shall have been taken or arisen outside the Territory
which is similar or analogous to any of the steps or events listed at (a)
to (d) above; or
(f) that Party suspends or threatens to suspend making payments to all or some
of that Party's creditors or the Party submits to any type of voluntary
arrangement; or
(g) where that Party is resident in the Territory it is deemed to be unable to
pay its debts within the meaning of Xxxxxxx 000 Xxxxxxxxxx Xxx 0000;
"Novartis Products" means the pharmaceutical products listed in Part II of
Schedule 3.
"Party" means either Cephalon or Novartis and "Parties" means either of
them.
"Products" means the pharmaceutical products listed in Schedule 3 and such
other products as the Parties may agree from time to time.
"Quarter" means each consecutive period of three months and "Quarterly"
shall be construed accordingly.
"Rights" means all or any copyright, design right, trade marks, trade
names, patents, know-how, trade secrets and other intellectual property or
other proprietary rights in respect of or relating to the Products which
may at any time subsist throughout all or any part of the world (whether
registered or otherwise);
-4-
"Services" means those services required to be performed by Cephalon as
set out or referred to in Schedule 1.
"Staff" means Cephalon's employees, consultants or subcontractors engaged
in the provision of the Services.
"Subsidiary or Holding Company" have the meaning ascribed to those
expressions by Section 736 of the Companies Xxx 0000 (as amended).
"Term" means the period of 10 (ten) years from the Commencement Date.
"Territory" means the United Kingdom of Great Britain and Northern
Ireland, and in the case of the Cephalon Product only, the Republic of
Ireland.
"Working Day" means any day other than a Saturday, Sunday, bank or other
public holiday in the United Kingdom, USA or Switzerland.
"Year" means a period of 12 consecutive months, with the first such period
commencing on the Commencement Date.
1.2 In this Agreement:-
1.2.1 unless the context otherwise requires all references to a particular
Clause or Schedule shall be a reference to that Clause or Schedule
in or to this Agreement as it may be amended from time to time
pursuant to this Agreement;
-5-
1.2.2 the table of contents and headings are inserted for convenience only
and shall not affect the interpretation of any provision of this
Agreement;
1.2.3 unless the contrary intention appears words importing the masculine
gender shall include the feminine and vice versa and words in the
singular include the plural and vice versa;
1.2.4 unless the contrary intention appears words denoting persons shall
include any individual, partnership, company, corporation, joint
venture, trust, association, organisation or other entity, in each
case whether or not having separate legal personality;
1.2.5 reference to any statute or regulation includes any modification or
re-enactment of that statute or regulation;
1.2.6 reference to the words "include" or "including" are to be construed
without limitation to the generality of the preceding words; and
1.2.7 if there is any conflict or inconsistency between the terms and
conditions of Parts A-D herein and the Schedules, such conflict or
inconsistency shall be resolved in accordance with the following
order of priority:
(a) the terms and conditions of Parts A-D herein;
(b) Schedule 1;
(c) Schedule 2;
-6-
2. Cephalon's Responsibilities and Obligations
2.1 Cephalon shall provide the Services to Novartis from the Commencement Date
subject to and in accordance with the terms and conditions of this
Agreement.
2.2 Cephalon shall provide the Services as the same may be varied from time to
time by agreement between the Parties and with Staff as required. Unless
otherwise agreed in writing with Novartis, Cephalon shall only be obliged
to provide the Services in relation to the Products. Cephalon shall
perform the Services with all due care, diligence and attention and in
accordance with good industry practice prevailing from time to time.
2.3 Cephalon shall maintain sufficient resources (either its own employees or
through permitted sub-contractors) to provide the Services in respect of
the Products throughout the Territory and shall perform in a timely and
satisfactory manner Cephalon's obligations under this Agreement
2.4 Cephalon shall keep records and books of account relating to the provision
of the Services in accordance with generally accepted UK accounting
principles and Novartis shall be entitled to audit the same in accordance
with Clause 4.
2.5 Cephalon shall procure that in providing the Services the Staff will
comply with all relevant laws regulations and guidelines applicable to the
promotion and marketing of the Products and shall not do or omit to do
anything where such act or omission might prejudice Novartis' Rights or
reputation in the Territory.
-7-
2.6 Cephalon shall keep Novartis informed in writing in respect of any
complaint, claim, demand or dispute concerning the Novartis Products.
2.7 Cephalon shall advise Novartis within 48 hours of any reported Adverse
Reaction occurring in the Territory and reported to Novartis in respect of
the Novartis Products. Novartis shall have sole responsibility for
reporting Adverse Reactions to the Medicines Control Agency and will
conduct all communication relating to safety issues in relation to the
Novartis Products and Cephalon shall have sole responsibility for
reporting Adverse Reactions to the Medicines Control Agency and will
conduct all communication relating to safety issues in relation to the
Cephalon Product.
3. Novartis' Responsibilities And Obligations
3.1 Novartis shall perform all obligations it is required to perform as set
out or referred to in Schedule 1. If Novartis fails to perform any such
obligations, Cephalon shall not be liable for any failure to perform its
obligations under this Agreement and Novartis shall pay to Cephalon any
costs to Cephalon which result from such failure by Novartis to perform
its obligations under this Agreement.
3.2 Novartis represents and warrants that it has obtained and will maintain at
its own cost and expense all necessary permission consents and licences in
respect of the Novartis Products necessary for the provision of the
Services.
-8-
3.3 Novartis shall have responsibility for providing all training in relation
to the Novartis Products of suitable quality and detail as shall be
required to enable the Staff to provide the Services in relation to the
Novartis Products.
3.4 Novartis shall ensure that appropriate personnel from Novartis are
available to liaise and co-operate with the staff and shall co-operate
with Cephalon to ensure Cephalon's compliance with UK and European
legislation.
4. Audit
4.1 Cephalon shall keep true and accurate records and books of account
containing all data necessary for the calculation of the amounts charged
by it to Novartis pursuant to this Agreement. Those records and books of
account shall be kept for 7 years following the end of the calendar year
to which they relate. Upon Novartis' written request a firm of accountants
appointed by agreement between the Parties or, failing such agreement
within 10 Business Days of the initiation of discussions between them on
this point and at the request of either Party by the President for the
time being of the Institute of Chartered Accountants of England and Wales
in London and
4.1.1 such firm of accountants shall be given access to and shall be
permitted to examine and copy such books and records upon 20
Business Days notice having been given by Novartis and at all
reasonable times on Business Days for the purpose of certifying to
Novartis that the Charges calculated by Cephalon during any year was
reasonably calculated, true and accurate
-9-
or, if this is not their opinion certify the Charges figures for
such period which in their judgment are true and correct.
4.1.2 prior to any such examination taking place, such firm of accountants
shall undertake to Cephalon in a deed that they shall keep all
information and data contained in such books and records, strictly
confidential and shall not disclose such information or copies of
such books and records to any third person including Novartis, but
shall only use the same for the purpose of the calculations which
they need to perform in order to issue the certificate to Novartis
which this Clause 4 envisages.
4.1.3 any such access examination and certification shall occur no more
than once per year and will not go back over records more than 2
years old unless a discrepancy is found.
4.1.4 Cephalon shall make available personnel to answer queries on all
books and records required for the purpose of that certification.
4.1.5 the cost of the accountant shall be the responsibility of Cephalon
if the certification shows Cephalon to have overestimated the monies
payable by Novartis by more than 5% and the responsibility of
Novartis otherwise.
4.2 Within 10 Business Days following any such certification any monies which
such certification shows as being due and owing by one Party to the other
(whether because of an underpayment or overpayment) shall be paid by that
Party.
5. Payment
-10-
5.1 Novartis shall pay the Charges to Cephalon for the Services provided
hereunder monthly following receipt of invoice from Cephalon.
5.2 Payment for each invoice made hereunder shall be made by telegraphic
transfer to such bank account as Cephalon shall notify to Novartis from
time to time.
5.3 The currency for all payments under Clause 5.1 shall be in (pound)
sterling.
5.4 If Novartis fails to pay the Charges:
5.4.1 within 30 days after the date of the invoice therefor Cephalon shall
be entitled (without prejudice to any other right or remedy it may
have) to charge Novartis interest on the Charges (which shall accrue
from day to day after as well as before judgement) at the rate of 2%
per annum above National Westminster plc's base rate from time to
time in force from the date the payment became due until actual
payment is made, compounded monthly; and
5.4.2 within 30 days after the date of the invoice therefor Cephalon shall
be entitled (without prejudice to any other right or remedy it may
have) to cancel or suspend any further services to be provided to
Novartis.
5.5 All payments to be made by Novartis to Cephalon hereunder are exclusive of
value added tax which shall be payable if applicable to do so in addition
at the rate and in the manner for the time being prescribed by law.
-11-
6. Data Protection
6.1 Each Party warrants to the other that all personal data held by it to be
processed by the other under this Agreement has been or will be obtained
and processed (in so far as such data has been or will be so processed) in
accordance with the Data Protection Act 1998 (the "Act") and in a manner
which permits the other to perform its obligations under this Agreement in
compliance with the Act.
6.2 Each party warrants to the other that:
6.2.1 it is, and at all times during the term of this Agreement will be,
adequately and appropriately registered under the Act in order to comply
with its obligations under this Agreement; and
6.2.2 it will at all times during the term of this Agreement comply with the Act
in performing its obligations under this Agreement.
7. Rights
7.1 Any Rights created by the Staff in the course of providing the Services to
Novartis under this Agreement shall remain the property of Cephalon save
that to the extent the same relate to Novartis Products they shall become
the property of Novartis and Cephalon shall take all steps reasonably
necessary to vest the same in Novartis.
7.2 Any Rights created by employees of Novartis in the course of performing
the obligations of Novartis hereunder shall remain the property of
Novartis save that to the extent the same relate to Cephalon Products they
shall become the property of
-12-
Cephalon and Novartis and shall take all steps reasonably necessary to
vest the same in Cephalon.
8. Duration and Termination
8.1 This Agreement shall commence on the Commencement Date and shall continue
for the Term unless terminated in accordance with Clause 9.
9. Termination
9.1 Either party may terminate this Agreement on 30 (thirty) days' written
notice to the other if Control of the other or any of that Party's
Controllers shall pass from the present shareholders or owners or
Controllers to other persons,
9.2 Without prejudice to any right or remedy that either Party may have
against the other for breach or non-performance of this Agreement, either
Party shall have the right to terminate the Agreement immediately:
9.2.1 On the other party committing a breach of any of the provisions of
any of the Agreement providing that (where the breach is capable of
rectification) the Party in breach has been advised in writing of
the breach and has not rectified in within 30 (thirty) days of
receipt of such advice, or
9.2.2 If an Insolvency Event occurs in relation to the other Party.
-13-
9.3 All provisions which expressly or impliedly survive the termination of
this Agreement shall remain in force notwithstanding the expiry or
termination of this Agreement.
10. Consequences of Termination
10.1 Upon termination of this Agreement, Cephalon shall immediately cease to
provide the Services.
10.2 In the event of termination of this Agreement (other than following a
breach of contract by Cephalon), Novartis shall pay to Cephalon all costs
of Cephalon associated with such termination including, without
limitation, all transition costs Cephalon incurs in redeploying Staff.
11. Exclusion Of Implied Warranties
All warranties, conditions and representations in relation to the Services to
be provided by Cephalon except as expressly provided herein and any other
obligation of Cephalon under this Agreement, whether express or implied by
statute, custom, law or usage, are expressly excluded from this Agreement.
12. Indemnity
12.1 If any claim against either Party, its Affiliates, recognised distributors
or agents (the "Indemnified Party") is brought by reason of the fact that
any Product belonging to the other Party (Cephalon Products where Novartis
is the Indemnified Party and Novartis Products where Cephalon. is the
Indemnified Party) has caused illness,
-14-
death or bodily injury, then unless such claim is a result solely of the
gross negligence or misconduct of the Indemnified Party, Novartis or
Cephalon (as the case may be) shall indemnify the other and its Affiliates
for any and all liabilities, claims, damages and costs incurred or
suffered by the other Party or its Affiliates or recognised distributors,
and for any and all other liabilities, claims, damages and costs suffered
by such Party or its Affiliates, as a result of any associated Product
recall, final packaging and similar costs associated with such Product.
Such indemnity will include the reimbursement of the legal expenses
reasonably incurred in contesting or defending such claim.
12.2 Each Party shall give the other Party prompt written notice of any claim
or threat of claim it receives with respect to any matter for which it or
its Affiliates may be entitled to indemnification, and the indemnifying
Party shall thereafter defend or settle any such claim at its sole
expense, and with counsel selected by the indemnifying Party and
reasonably acceptable to the Indemnified Party. In the defence or
settlement of any such claim, the Indemnified Party shall cooperate with
and assist the indemnifying Party to the extent reasonably possible, but
the indemnifying Party shall bear and pay any and all expenses incurred by
the Indemnified Party in providing such cooperation and assistance, either
directly or upon request of the Indemnified Party who has incurred such
expense. Failure to give notice shall not constitute a defence, in whole
or in part, to any claim by the Indemnified Party hereunder except to the
extent the rights of the indemnifying Party are materially prejudiced by
such failure to give notice.
13. Force Majeure
-15-
13.1 If a Party (the "Non-Performing Party") is unable to carry out any of its
obligations under this Agreement due to Force Majeure this Agreement shall
remain in effect but:-
13.1.1 the Non-Performing Party's relevant obligations under this
Agreement; and
13.1.2 the relevant obligations of the other Party ("the Innocent Party")
under this Agreement,
shall be suspended for a period equal to the circumstance of Force Majeure
or 3 months whichever is the shorter provided that:-
(a) the suspension of performance is of no greater scope than is
required by the Force Majeure;
(b) the Non-Performing Party gives the Innocent Party prompt
notice describing the circumstance of Force Majeure, including
the nature of the occurrence and its expected duration, and
continues to furnish regular reports during the period of
Force Majeure;
(c) the Non-Performing Party uses all reasonable efforts to remedy
its inability to perform and to mitigate the effects of the
circumstance of Force Majeure; and
-16-
(d) a soon as practicable after the event which constitutes Force
Majeure the Parties discuss how best to continue their
operations as far as possible in accordance with this
Agreement.
14. Sub-contracting
14.1 Cephalon may subcontract the performance of some or all of its obligations
hereunder to third parties provided always that Cephalon shall remain
responsible for ensuring such obligations are complied with in accordance
with the terms of this Agreement
14.2 If Novartis shall be dissatisfied with the performance of services by
Cephalon's sub-contractors, the parties shall in good faith consider
measures to address the causes of such dissatisfaction. If notwithstanding
such measures (or if no measures are appropriate), Cephalon will terminate
the services of such subcontractor forthwith upon being required to do so
by Novartis and shall appoint a replacement sub-contractor nominated by
Novartis.
15. Notices
15.1 Any notice to be given in connection with this Agreement shall be in
writing and shall be deemed duly served if delivered personally or sent by
first class or recorded delivery post or by facsimile to the Company
Secretary at the address of the Party concerned which is set out in this
Agreement or as may be notified to the other Party in accordance with the
provisions of this Clause. Any notices which are sent
-17-
by e-mail shall not be valid unless and until confirmed by personal
delivery, first class or recorded delivery post or by facsimile.
15.2 Any such notice shall be deemed to be served:
15.2.1 if delivered personally, on the day on which it is delivered;
15.2.2 if sent by post, 5 Working Days after the time of posting;
15.2.3 if sent by facsimile, on acknowledgement by the recipient's
facsimile receiving equipment on a Working Day if the
acknowledgement occurs before 1700 hours local time of the recipient
and in any other case on the following Business Day.
16. Relationship of Parties
16.1 This Agreement shall not operate so as to create any of the following
relationships between the Parties:
16.1.1 partnership;
16.1.2 agency;
16.1.3 joint venture; or
16.1.4 employer/employee.
16.2 This Agreement shall not permit or authorise either Party to:
16.2.1 incur any expenses on behalf of the other Party;
-18-
16.2.2 enter into any commitment or make any representation or warranty on
behalf of the other Party;
16.2.3 pledge the credit of, or otherwise bind or oblige the other Party;
or
16.2.4 commit the other Party in any way whatsoever
without in each case obtaining the other Party's prior written consent.
17. Waiver
17.1 In no event shall any delay, failure or omission on the part of any Party
in enforcing exercising or pursuing any right, power, privilege, claim or
remedy, which is conferred by this Agreement, or arises under this
Agreement, or arises from any breach by the other Party to this Agreement
of any of its obligations tinder this Agreement, be deemed to be or be
construed as:
17.1.1 a waiver thereof, or of any other such right power privilege claim
or remedy, in respect of the particular circumstances in question;
or
17.1.2 operate so as to bar the enforcement or exercise thereof, or of any
other such right, power, privilege, claim or remedy, in any other
instance at any time or times afterwards.
18. Severability
Any provision of this Agreement which is held invalid or unenforceable in
any jurisdiction shall be ineffective to the extent of such invalidity or
unenforceability
-19-
without invalidating or rendering unenforceable the remaining provisions
hereof, and any such invalidity or unenforceability in any jurisdiction
shall not invalidate or render unenforceable such provisions in any other
jurisdiction
19. Third Party Rights
Nothing in this Agreement is intended to confer on any person any right to
enforce any term of this Agreement which that person would not have had
but for the Contracts (Rights of Third Parties) Xxx 0000.
20. Governing Law
This Agreement is governed by and shall be construed in accordance with
the laws of England and the Parties hereby submit to the non-exclusive
jurisdiction of the English Courts .
21. Transmission of Rights
Neither Party shall assign the benefit and/or the burden of this Agreement
to any third party without the prior written consent of the other.
22. Variations
Except as provided herein, this Agreement may not be amended, varied or
modified except in writing signed by a duly authorised officer or
representative of each of the Parties.
-20-
23. Counterparts
This Agreement may be executed in any number of counterparts and by the
Parties on separate counterparts, each of which when so executed shall be
an original of this Agreement, and all of which shall together constitute
one and the same instrument. Complete sets of counterparts shall be lodged
with each Party.
-21-
IN WITNESS WHEREOF the parties have executed this Agreement the day and year
first above written.
SIGNED by )
for and on behalf of ) J. Xxxxx Xxxxx
CEPHALON (UK) LIMITED )
in the presence of: )
Xxxx Xxx Xxxx
SIGNED by )
for and on behalf of ) Xxxxxx Xxxxx
NOVARTIS PHARMACEUTICALS )
UK LIMITED )
in the presence of: )
Xxxxx Xxxxxxxxx
-22-
Schedule 1
Services
Obligations of CEPHALON
1. Provision and maintenance of Staff, including equipment and relevant
training.
2. Provision of marketing and other promotion activities.
3. Clinical and Technical Development Services - including new formulation
and new agreed indication development (these being Obstructive Sleep
Apnoea, attention deficit hyperactivity disorder and fatigue associated
with MS).
4. Regulatory services - maintaining regulatory compliance of non-Novartis
Products (not including new indication or new formulation license
applications or renewals).
5. Medical Information services for ALL products (with reference to Novartis
Med Info resources when necessary) and Pharmacovigilance services for all
non-Novartis Products.
6. Provision of facilities (premises and associated costs) reasonably
necessary to perform the Services.
7. Provision of administrative support - including administration of all
activities, accounting services, IT support.
8. Conduct necessary Phase IV studies, up to budgeted levels of expenditure.
9. Such other things as may be agreed from time to time.
Obligations of NOVARTIS in respect of Novartis Products in the Territory
1. Provision of adequate training to sales force in respect of the Novartis
Products.
2. Provision of expertise and advice regarding marketing, promotion and
development.
3. Provisions of access to information sources and databases.
4. Access to Med Info DB's etc for Medical Information and Pharmacovigilance
purposes.
5. Access to all available promotion materials in the Territory.
-23-
6. Regulatory advice.
7. Maintain Regulatory Compliance of all Novartis Products (not including new
indication or new formulation licence applications or renewals).
8. Such other things as may be agreed from time to time.
-24-
Schedule 2
Charges
All charges incurred in reorganising the operations of Cephalon to accommodate
the provisions of this agreement, whether incurred before, during or after the
term of the agreement will be chargeable
The charges levied by Cephalon will be based on:
i) those costs directly attributable to the services
provided; and
ii) in the case of fixed and non-direct costs, a proportion based |_| on either
direct costs / total costs by department, or some other |_| suitable measure
(i.e. floor space, activity levels)
-25-
Schedule 3
The Products
Part 1 - Cephalon Product
Brand Name/Active Ingredient Pack Size (SKU)
PROVIGIL/modafanil 100mg tabs - 30
Part II - Novartis Products
Brand Name/Active Ingredient Pack Size (SKU)
ANAFRANIL - clomipramine 10mg caps - 84
hydrochloride
25mg caps - 84
50mg caps - 56
ANAFRANIL SR 75mg tab - 28
ANAFRANIL SYRUP 25mg/5ml - 150ml
ANAFRANIL INJECTION 25mg/25ml amp - 10
LIORESAL - baclofen 10mg tab - 84
LIORESAL LIQUID 5mg/5ml - 300ml
(excluding sales for use in intrathecal pumps)
RITALIN - methylphenidate 10mg tab - 30
TEGRETOL - carbamazepine 100mg tab - 84
200mg tab - 84
400mg tab - 00
XXXXXXXX XXXXXXX 100mg - 56
200mg - 56
-00-
XXXXXXXX XXXXXX 200mg - 56
400 mg - 56
TEGRETOL LIQUID 100mg/5ml - 300ml
TEGRETOL SUPPS 125mg - 5
250mg - 5
The Products shall include essentially similar products.
-27-